Abstract
BACKGROUND: The common area of breast cancer metastases are bone, lung and liver. Brachial plexus metastasis from breast cancer is extremely rare. We report a case of subclavian brachial plexus metastasis from breast cancer 6 years postoperative, which were detected by ultrasound, magnetic resonance imaging (MRI) and (18)F-fluorodeoxyglucose positron emission tomography and computed tomography (FDG-PET/CT). CASE SUMMARY: Our study reports a 64-year-old woman who had right breast cancer and underwent radical mastectomy 6 years before. Ultrasound first revealed a soft lesion measuring 38 mm × 37 mm which located on the right side of the clavicle to the armpit subcutaneously. The right subclavian brachial plexus (beam level) was significantly thickened, wrapped around by a hypoechoic lesion, the surrounded axillary artery and vein were pressed. MRI brachial plexus scan showed that the right side of brachial plexus was enlarged compared with the left side and brachial plexus bundle in the distance showed a flake shadow. FDG-PET/CT revealed that the right side of brachial plexus nodular appearance with increased FDG metabolism. These results supported brachial plexus metastasis from breast cancer. Ultrasound exam also found many lesions between pectoralis major, deltoid muscle and inner upper arm. The lesion puncture was performed under ultrasound guidance and the tissue was sent for pathology. Pathology showed large areas of tumor cells in fibroblast tissue. Immunohistochemistry showed the following results: A2-1: GATA3 (+), ER (+, strong, 90%), PR (+, moderate, 10%), HER-2 (3+), Ki67 (+15%), P120 (membrane+), P63 (-), E-cadherin (+), CK5/6 (-). These results were consistent with the primary right breast cancer characteristics, thus supporting lesion metastasis from breast cancer. CONCLUSION: The brachial plexus metastasis from breast cancer is uncommon. Ultrasound has great value in detecting brachial plexus metastasis of breast cancer. It is an easy, non-invasive and affordable method. Close attention should be paid to new grown out lesions in those patients who had a history of breast cancer when doing ultrasound review.